Disease-A-Month
Volume 57, Issue 1 , Pages 40-54 , January 2011

Mesothelioma

References 

  1. National Comprehensive Cancer Network. Practice Guidelines in Oncology: Malignant Pleural mesothelioma. 2010;http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
  2. Ismail-Khan R, Robinson LA, Williams CC, et al. Malignant Pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255–263
  3. Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009;153(4):143–152
  4. In:  Fishman AP editors. Fishman's Pulmonary Diseases and Disorders. 4th ed.. McGraw-Hill Medical; 2008;
  5. Reid A, de Klerk N, Ambrosini G, et al. The additional risk of malignant pleural mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med. 2005;62(10):665–669
  6. Luo S, Liu X, Mu S, et al. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China (I. Review of exposure and epidemiological data). Occup Environ Med. 2003;60(1):35–42
  7. Abratt RP, Vorobiof DA, White N. Asbestos and mesothelioma in South Africa. Lung Cancer. 2004;45(suppl 1):S3–S6
  8. Huncharek M. Non-asbestos related diffuse malignant mesothelioma. Tumori. 2002;88(1):1–9
  9. Cvitanovic S, Znaor L, Konsa T, et al. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study. Croat Med J. 2003;44(5):618–625
  10. Carbone M, Bedrossian C. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006;23(1):56–60
  11. Dogan AU, Baris YI, Dogan M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006;66(10):5063–5068
  12. Hirvonen A, Tuimala J, Ollikainen T, et al. Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders. Cancer Lett. 2002;178(1):71–74
  13. Kumar V, Cotran RS, Robbins SL. Robbins and Cotran: Pathologic Basis of Disease. 7th ed.. Philadelphia, PA: Elsevier Saunders; 2005;
  14. Nowak AK, Armato SG, Ceresoli GL, et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer. 2010;70(1):1–6
  15. Armato SG, Entwisle J, Truong MT, et al. Current state and future directions of pleural mesothelioma imaging. Lung Cancer. 2008;59(3):411–420
  16. Gill RR, Umeoka S, Mamata H, et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol. 2010;195(2):W125–W130
  17. Geisel FL, Bischoff H, von Tengg-Kobligk H, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of non-invasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129(6):1570–1576
  18. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129(11):1407–1414
  19. Bhalla R, Siddiqui MT, Mandish D, et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 2007;35(6):342–347
  20. Schneider J, Hoffmann H, Deinemann H, et al. Diagnostic and prognostic value of soluble mesothelinrRelated proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317–1324
  21. Yasumitu A, Tabata C, Tabata R, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5(4):479–483
  22. Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 2010;48(2):271–278
  23. Sculier JP, Berghmans T, Meert AP. Update in lung cancer and mesothelioma 2009. Am J Respir Crit Care Med. 2010;181(8):773–781
  24. Hanna A, Pang Y, Bedrossian CW, et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010;38(4):264–269
  25. Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med. 2001;95(10):829–835
  26. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res. 2010;16(8):2409–2417
  27. Kumas P, Mratzke RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer. 2005;49(suppl 1):S53–S60
  28. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–626
  29. Nakas A, Martin Ucar AE, Edwards JG, et al. The role of thorascopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;33(1):83–88
  30. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84(5):1685–1693
  31. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63(4):1045–1052
  32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644
  33. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–3013
  34. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413–1418
  35. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88(3):870–876
  36. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer. 2001;31(2-3):303–310
  37. Takemura Y, Satoh M, Satoh K, et al. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun. 2010;394(2):249–253

PII: S0011-5029(10)00210-5

doi: 10.1016/j.disamonth.2010.12.004

Disease-A-Month
Volume 57, Issue 1 , Pages 40-54 , January 2011

Article Tools

* Image Usage & Resolution